Goodman, MD, a professor at Mt. Sinai School of Medicine in New York. I think it would be a mistake to take the risk of leaving as a class III [device], and enabling it to be withdrawn. ‘New WarningsSome experts fear that the need for new data could hinder access to ECT for severely ill patients who do not receive any help from other treatments.
Hundreds of patients have complained to the FDA have not been advised of the possibility of memory loss, cognitive impairment, and other problems before they underwent ECT.
I believe that the data is lacking on how we can better mitigate the risks, said Jane Paulsen, Ph.D., a researcher in neuropsychology at the University of Iowa.
If the FDA maintains its more restrictive class III designation for ECT, companies must submit applications demonstrating their machines are safe and effective. They can be exceeded or not exist at all for many devices, prompting fears that some machines may be forced to exit the market.
Of more concern to the FDA is the risk of cognitive side effects, such as loss of memory, especially after prolonged use of ECT. While most experts agree that the benefits of short-term ECT treatments outweigh the risks for severely depressed patients, few studies examine the effects of six months, according to experts.
Members of the Advisory Committee also urged the agency to find new warnings clear to patients and improve consent forms detailing the benefits and risks. This perspective can be complex, as patients with mental disorders who are candidates for ECT may not be able to fully understand the risks.
ECT machines have escaped scrutiny by the FDA in large part because they were already on the market, when the agency tightened the rules of three decades ago. The treatment is generally considered effective for patients who have few other options. But concerns about the long-term safety have prompted new attention of regulators.
Do not feel you were adequately informed, said Malvina Eydelman, director of FDA’s division of ophthalmic surgical, neurological, and Ear, and Throat Devices. This was certainly a problem.
The recommendations of an FDA advisory committee could mean new restrictions on electroconvulsive therapy – a controversial treatment used by tens of thousands of patients with mental disorders and other Americans.
At week 24, patients significantly higher in the certolizumab pegol treatment MCID reported improvements in all six PRO , physical function by HAQ, and HRQOL by SF-36 physical and mental component summary scores). The beneficial effects of certolizumab pegol were similar between the levels of 200 mg and 400 mg, no significant difference between treatment groups during PROs.1